Nothing Special   »   [go: up one dir, main page]

ES2721930T3 - Composición inmunogénica - Google Patents

Composición inmunogénica Download PDF

Info

Publication number
ES2721930T3
ES2721930T3 ES13801540T ES13801540T ES2721930T3 ES 2721930 T3 ES2721930 T3 ES 2721930T3 ES 13801540 T ES13801540 T ES 13801540T ES 13801540 T ES13801540 T ES 13801540T ES 2721930 T3 ES2721930 T3 ES 2721930T3
Authority
ES
Spain
Prior art keywords
fragment
immunogenic composition
toxin
isolated
clostridium difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13801540T
Other languages
English (en)
Inventor
Dominique Boutriau
Sophie Marie Jeanne Valentine Germain
Hugues Wallemacq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2721930T3 publication Critical patent/ES2721930T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición inmunogénica que comprende: a) un polipéptido que comprende un fragmento aislado de toxina A de Clostridium difficile y un fragmento aislado de toxina B de Clostridium difficile; y b) un coadyuvante que comprende una fracción de saponina inmunológicamente activa presentada en forma de un liposoma; en la que el polipéptido comprende un fragmento del dominio de repetición de la toxina A y un fragmento del dominio de repetición de la toxina B.
ES13801540T 2012-12-05 2013-12-03 Composición inmunogénica Active ES2721930T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201221875 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Publications (1)

Publication Number Publication Date
ES2721930T3 true ES2721930T3 (es) 2019-08-06

Family

ID=49724573

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13801540T Active ES2721930T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica
ES19159001T Active ES2939307T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19159001T Active ES2939307T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica

Country Status (22)

Country Link
US (2) US9694064B2 (es)
EP (2) EP3513806B1 (es)
JP (2) JP6290918B2 (es)
CN (2) CN104884081A (es)
AR (1) AR093712A1 (es)
AU (1) AU2013354186A1 (es)
BR (1) BR112015012841B1 (es)
CA (1) CA2893435A1 (es)
CY (1) CY1121560T1 (es)
DK (2) DK2928489T3 (es)
ES (2) ES2721930T3 (es)
FI (1) FI3513806T3 (es)
HR (2) HRP20230359T1 (es)
HU (2) HUE043091T2 (es)
LT (2) LT3513806T (es)
PL (2) PL3513806T3 (es)
PT (2) PT2928489T (es)
SG (1) SG11201503861UA (es)
SI (2) SI3513806T1 (es)
TR (1) TR201905272T4 (es)
WO (1) WO2014086787A1 (es)
ZA (1) ZA201503927B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2283857T (pt) * 2005-06-27 2019-10-24 Glaxosmithkline Biologicals Sa Composição de vacina compreendendo polissacáridos capsulares nativos conjugados de n. meningitidis.
EP2753352B2 (en) 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
PL3513806T3 (pl) * 2012-12-05 2023-05-15 Glaxosmithkline Biologicals Sa Imunogenna kompozycja
EP3636278A3 (en) * 2014-06-25 2020-07-15 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
EP3271375B1 (en) 2015-02-19 2021-02-24 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
CN109311950A (zh) 2016-03-21 2019-02-05 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201908376UA (en) * 2017-03-15 2019-10-30 Novavax Inc Methods and compositions for inducing immune responses against clostridium difficile
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California VACCINE COMPOSITION FOR CLOSTRIDIUM DIFFICILE
US20230218735A1 (en) * 2020-06-19 2023-07-13 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
TW202438104A (zh) * 2022-12-13 2024-10-01 美商輝瑞股份有限公司 誘發針對困難梭狀芽孢桿菌之免疫反應的免疫原性組成物和方法
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5750110A (en) 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
NZ337543A (en) 1994-10-24 2002-06-28 Allergan Inc Composition comprising avian antitoxin against clostridial neurotoxin protein and method for producing recombinant antitoxin proteins are provided for
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2307331C (en) 1997-10-20 2017-03-21 Oravax, Inc. Passive immunization against clostridium difficile disease
WO2000061762A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
KR101151202B1 (ko) * 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
GB0711858D0 (en) 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
JP5503543B2 (ja) 2007-09-14 2014-05-28 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
CN102099052A (zh) 2008-04-16 2011-06-15 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
EP2753352B2 (en) * 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
CA2837393A1 (en) 2011-05-27 2012-12-06 Glaxosmithkline Biologicals S.A. Immunogenic composition
PL3513806T3 (pl) * 2012-12-05 2023-05-15 Glaxosmithkline Biologicals Sa Imunogenna kompozycja

Also Published As

Publication number Publication date
CY1121560T1 (el) 2020-05-29
PL2928489T3 (pl) 2019-07-31
EP2928489B1 (en) 2019-02-27
HUE061273T2 (hu) 2023-06-28
JP6626521B2 (ja) 2019-12-25
JP6290918B2 (ja) 2018-03-07
PL3513806T3 (pl) 2023-05-15
PT3513806T (pt) 2023-03-02
JP2018104446A (ja) 2018-07-05
WO2014086787A1 (en) 2014-06-12
FI3513806T3 (fi) 2023-04-26
DK2928489T3 (en) 2019-04-23
HUE043091T2 (hu) 2019-08-28
ZA201503927B (en) 2017-11-29
EP2928489A1 (en) 2015-10-14
LT3513806T (lt) 2023-04-11
US20150313984A1 (en) 2015-11-05
ES2939307T3 (es) 2023-04-20
US10130694B2 (en) 2018-11-20
DK3513806T5 (da) 2024-09-02
CA2893435A1 (en) 2014-06-12
US9694064B2 (en) 2017-07-04
BR112015012841B1 (pt) 2022-05-03
PT2928489T (pt) 2019-05-28
BR112015012841A2 (pt) 2017-09-26
HRP20230359T1 (hr) 2023-06-09
TR201905272T4 (tr) 2019-05-21
LT2928489T (lt) 2019-04-10
AR093712A1 (es) 2015-06-17
SG11201503861UA (en) 2015-06-29
EP3513806B1 (en) 2023-01-25
CN104884081A (zh) 2015-09-02
SI3513806T1 (sl) 2023-04-28
EP3513806A1 (en) 2019-07-24
US20170340719A1 (en) 2017-11-30
DK3513806T3 (da) 2023-02-27
AU2013354186A1 (en) 2014-06-12
CN112807422A (zh) 2021-05-18
HRP20190711T1 (hr) 2019-05-31
JP2016502551A (ja) 2016-01-28
SI2928489T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
ES2721930T3 (es) Composición inmunogénica
MX2015015239A (es) Composiciones y metodos.
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
BR112013000599A2 (pt) deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
AR101455A1 (es) Molécula portadora
SI2909307T1 (sl) Kompozicije in metode, povezane z mutantnim toksinom clostridium difficile
BR112015021880A2 (pt) rearranjo de vírus influenza b
UY4210Q (es) Silla
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
TWD162230S (zh) 啤酒分配器
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
UY4238Q (es) Silla con respaldo en forma trapezoidal
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
TWD162231S (zh) 啤酒分配器
AR088908A1 (es) Vacuna
EA201390670A1 (ru) Новый адъювант
GB201106162D0 (en) Combination vaccine
IN2014DN00168A (es)
TWD186746S (zh) 破碎機
CL2013000490S1 (es) Aspiradora
TWD162356S (zh) 眼鏡
TWD160691S (zh) 眼鏡